Skip to main content

Table 4 Main and secondary outcomes for website groups at six week follow up

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable

Website

Website + support

No website group

Significance

IBS-SSS total mean (n = 123)

197.0 (172.4 - 221.7)

208.0 (188.1 - 233.0)

162.8 (137.4 -188.3)

p = 0.037*

IBS-QOL score (n = 123)

71.6 (67.9-75.2)

67.6 (63.9-71.3)

69.4 (65.7-73.1)

p = 0.315

HADS score for anxiety (n = 114)

8.9 (7.9-9.8)

9.7 (8.8-10.6)

8.3 (7.3-9.2)

p = 0.109

HADS score for depression (n = 114) (%)

   

p = 0.122

Normal (0–7)

35 (89.7)

28 (71.8)

31 (79.5)

 

Mild (8–10)

2 (5.1)

8 (20.5)

8 (20.5)

 

Moderate or Severe (11–21)

2 (5.1)

3 (7.7)

0 (0)

 

Enablement score (n = 113) (%)

   

p = 0.000**

0

7 (18.4)

4 (10.5)

21 (56.8)

 

1-2

7 (18.4)

5 (13.2)

4 (10.8)

 

3-5

13 (34.2)

15 (39.5)

7 (18.9)

 

6-12

11 (28.9)

14 (36.8)

5 (13.5)

 
  1. Analysis of the 6 week follow-up scores.
  2. ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression and Enablement (n (%).